Introduction

Alkermes is a biotechnology company focused on drug development process from a patient-centric perspective, beginning with a thorough understanding of the challenges patients face on a day-to-day basis. The company's acquisition of Medisorb Technologies and Advanced Inhalation Research (AIR) in 1996 and 1996 have resulted Alkermes in emerging as strong player with proven proprietary technologies.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Alkermes develops innovative medicines based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases and improve patient's lives. The company has two commercial products: Risperdal Consta (risperidone), a long-acting atypical antipsychotic medication for schizophrenia and Vivitrol (naltrexone for extended-release injectable suspension), the first and only once-monthly injectable medication for the treatment of alcohol dependence Its product candidates include ALKS 29 for alcohol dependence, AIR Inhaled Insulin (AIR Insulin) for diabetes, Exenatide LAR for Type 2 diabetes and AIR PTH for Osteoporosis. It enters into collaborations with pharmaceutical and biotechnology companies to develop new product candidates based on existing drugs incorporating its technologies.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization.

Report Highlights

[Studien Infos ausblenden]